Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.